Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Sep;18(3):401–410. doi: 10.1111/j.1365-2125.1984.tb02482.x

A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients.

E Perucca, A Hedges, K A Makki, M Ruprah, J F Wilson, A Richens
PMCID: PMC1463658  PMID: 6435654

Abstract

The antipyrine clearance and the urinary excretion of D-glucaric acid (D-GA) were determined in 122 patients receiving chronic anticonvulsant drug treatment and in 21 drug-free control subjects. Patients treated with carbamazepine (CBZ), phenytoin (DPH), primidone (PMD) and phenobarbitone (PB), either alone or in combination, showed higher values of antipyrine clearance and excreted larger amounts of D-GA as compared to controls. While antipyrine clearance values did not differ significantly from one drug group to another, D-GA excretion was significantly higher in patients treated with CBZ than in those treated with DPH. In patients treated with sodium valproate antipyrine clearance did not differ from control values. There was a trend for D-GA excretion to be higher in these patients but the difference was not statistically significant. Significant positive correlations were found between the dosage of CBZ, DPH, PMD and PB and both indices of enzyme induction. These data demonstrate a dose-dependent degree of enzyme induction in patients receiving therapeutic doses of these anticonvulsants. The relative potency at average dose levels for antipyrine clearance was PB (1), DPH (0.92), CBZ (0.84), PMD (0.82) and for log D-GA excretion was PB (1), CBZ (0.96), PMD (0.95), DPH (0.90).

Full text

PDF
401

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bonkowsky H. L., Sinclair P. R., Emery S., Sinclair J. F. Seizure management in acute hepatic porphyria: risks of valproate and clonazepam. Neurology. 1980 Jun;30(6):588–592. doi: 10.1212/wnl.30.6.588. [DOI] [PubMed] [Google Scholar]
  2. Breckenridge A., Orme M. L., Davies L., Thorgeirsson S. S., Davies D. S. Dose-dependent enzyme induction. Clin Pharmacol Ther. 1973 Jul-Aug;14(4):514–520. doi: 10.1002/cpt1973144part1514. [DOI] [PubMed] [Google Scholar]
  3. Danhof M., Verbeek R. M., van Boxtel C. J., Boeijinga J. K., Breimer D. D. Differential effects of enzyme induction on antipyrine metabolite formation. Br J Clin Pharmacol. 1982 Mar;13(3):379–386. doi: 10.1111/j.1365-2125.1982.tb01389.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fraser H. S., Mucklow J. C., Bulpitt C. J., Kahn C., Mould G., Dollery C. T. Environmental factors affecting antipyrine metabolism in London factory and office workers. Br J Clin Pharmacol. 1979 Mar;7(3):237–243. doi: 10.1111/j.1365-2125.1979.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Garcia-Merino J. A., Lopez-Lozano J. J. Risks of valproate in porphyria. Lancet. 1980 Oct 18;2(8199):856–856. doi: 10.1016/s0140-6736(80)90196-8. [DOI] [PubMed] [Google Scholar]
  6. Guengerich F. P. Isolation and purification of cytochrome P-450, and the existence of multiple forms. Pharmacol Ther. 1979;6(1):99–121. doi: 10.1016/0163-7258(79)90057-3. [DOI] [PubMed] [Google Scholar]
  7. Hunter J., Maxwell J. D., Carrella M., Stewart D. A., Williams R. Urinary D-glucaric-acid excretion as a test for hepatic enzyme induction in man. Lancet. 1971 Mar 20;1(7699):572–575. doi: 10.1016/s0140-6736(71)91166-4. [DOI] [PubMed] [Google Scholar]
  8. Lecamwasam D. S. Hepatic enzyme induction and its relationship to urinary D-glucaric acid excretion in man. Br J Clin Pharmacol. 1975 Dec;2(6):546–548. doi: 10.1111/j.1365-2125.1975.tb00576.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Levy R. H., Koch K. M. Drug interactions with valproic acid. Drugs. 1982 Dec;24(6):543–556. doi: 10.2165/00003495-198224060-00004. [DOI] [PubMed] [Google Scholar]
  10. Makki K. A., Perucca E., Richens A. Stimulation of drug metabolism by folate replacement in folate-deficient epileptic patients [proceedings]. Br J Clin Pharmacol. 1980 Mar;9(3):304P–305P. doi: 10.1111/j.1365-2125.1980.tb04861.x. [DOI] [PubMed] [Google Scholar]
  11. Marsh C. A. Metabolism of d-glucuronolactone in mammalian systems. Identification of d-glucaric acid as a normal constituent of urine. Biochem J. 1963 Jan;86(1):77–86. doi: 10.1042/bj0860077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Németh I., Szeleczki T. Increased D-glucaric acid excretion in children with renal disease. Int J Clin Pharmacol Ther Toxicol. 1980;18(8):357–360. [PubMed] [Google Scholar]
  13. Ohnhaus E. E., Gerber-Taras E., Park B. K. Enzyme-inducing drug combinations and their effects on liver microsomal enzyme activity in man. Eur J Clin Pharmacol. 1983;24(2):247–250. doi: 10.1007/BF00613826. [DOI] [PubMed] [Google Scholar]
  14. Ohnhaus E. E., Park B. K. Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur J Clin Pharmacol. 1979 Mar 26;15(2):139–145. doi: 10.1007/BF00609878. [DOI] [PubMed] [Google Scholar]
  15. Oxley J., Hedges A., Makki K. A., Monks A., Richens A. Lack of hepatic enzyme inducing effect of sodium valproate. Br J Clin Pharmacol. 1979 Aug;8(2):189–190. doi: 10.1111/j.1365-2125.1979.tb05821.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Park B. K., Breckenridge A. M. Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet. 1981 Jan-Feb;6(1):1–24. doi: 10.2165/00003088-198106010-00001. [DOI] [PubMed] [Google Scholar]
  17. Pirttiaho H. I., Sotaniemi E. A., Pelkonen R. O., Pitkänen U. Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants. Eur J Clin Pharmacol. 1982;22(5):441–445. doi: 10.1007/BF00542550. [DOI] [PubMed] [Google Scholar]
  18. Roots I., Holbe R., Hövermann W., Nigam S., Heinemeyer G., Hildebrandt A. G. Quantitative determination by HPLC of urinary 6beta-hydroxycortisol, an indicator of enzyme induction by rifampicin and antiepileptic drugs. Eur J Clin Pharmacol. 1979 Aug;16(1):63–71. doi: 10.1007/BF00644969. [DOI] [PubMed] [Google Scholar]
  19. Smith S. E., Rawlins M. D. Prediction of drug oxidation rates in man: lack of correlation with serum gamma-glutamyl transpeptidase and urinary excretion of D-glucaric acid and 6 beta-hydroxycortisol. Eur J Clin Pharmacol. 1974;7(1):71–75. doi: 10.1007/BF00614394. [DOI] [PubMed] [Google Scholar]
  20. Vesell E. S. The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clin Pharmacol Ther. 1979 Sep;26(3):275–286. doi: 10.1002/cpt1979263275. [DOI] [PubMed] [Google Scholar]
  21. de Wolff F. A., Peters A. C., van Kempen G. M. Valproate induces urinary D-glucaric acid excretion. Lancet. 1981 Apr 11;1(8224):843–843. doi: 10.1016/s0140-6736(81)92723-9. [DOI] [PubMed] [Google Scholar]
  22. van Boxtel C. J., Wilson J. T., Lindgren S., Sjöqvist F. Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man. Eur J Clin Pharmacol. 1976 Feb 6;9(4):327–332. doi: 10.1007/BF00561668. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES